Rocío Castellanos-Rueda

Rocío Castellanos-Rueda

Auto-generated profile, based on publicly available information

Rocío Castellanos-Rueda

Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
RCRocío Castellanos-Rueda
Rocío Castellanos-Rueda
RRRaphaël B. Di Roberto
Raphaël B. Di Roberto
FBFlorian Bieberich
Florian Bieberich
FSFabrice S. Schlatter
Fabrice S. Schlatter
DPDarya Palianina
Darya Palianina
SRSai T. Reddy
Sai T. Reddy
Chimeric antigen receptors (CARs) consist of an antigen-binding region fused to intracellular signaling domains, enabling customized T cell responses against targets. Despite their major role in T cell activation, effector function and persistence, only a small set of immune signaling domains have been explored. Here we present speedingCARs, an integrated method for engineering CAR T cells via signaling domain shuffling and pooled functional screening. Leveraging the inherent modularity of natural signaling domains, we generate a library of 180 unique CAR variants genomically integrated into primary human T cells by CRISPR-Cas9. In vitro tumor cell co-culture, followed by single-cell RNA sequencing (scRNA-seq) and single-cell CAR sequencing (scCAR-seq), enables high-throughput screening for identifying several variants with tumor killing properties and T cell phenotypes markedly different from standard CARs. Mapping of the CAR scRNA-seq data onto that of tumor infiltrating lymphocytes further helps guide the selection of variants. These results thus help expand the CAR signaling domain combination space, and supports speedingCARs as a tool for the engineering of CARs for potential therapeutic development.

4 January 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
XJXi Jiang
Xi Jiang
LPLucía Payá-Tormo
Lucía Payá-Tormo
DCDiana Coroian
Diana Coroian
IGInes Garcia
Ines Garcia
RCRocío Castellanos-Rueda
Rocío Castellanos-Rueda
Luis RubioLuis Rubio
Luis Rubio
Engineering nitrogen fixation in eukaryotes requires high expression of functional nitrogenase structural proteins, a goal that has not yet been achieved. Here we build a knowledge-based library containing 32 nitrogenase nifH sequences from prokaryotes of diverse ecological niches and metabolic features and combine with rapid screening in tobacco to identify superior NifH variants for plant mitochondria expression. Three NifH variants outperform in tobacco mitochondria and are further tested in yeast. Hydrogenobacter thermophilus (Aquificae) NifH is isolated in large quantities from yeast mitochondria and fulfills NifH protein requirements for efficient N2 fixation, including electron transfer for substrate reduction, P-cluster maturation, and FeMo-co biosynthesis. H. thermophilus NifH expressed in tobacco leaves shows lower nitrogenase activity than that from yeast. However, transfer of [Fe4S4] clusters from NifU to NifH in vitro increases 10-fold the activity of the tobacco-isolated NifH, revealing that plant mitochondria [Fe-S] cluster availability constitutes a bottleneck to engineer plant nitrogenases.

1 October 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSailan Shui
Sailan Shui
PGPablo Gainza
Pablo Gainza
LSLeo Scheller
Leo Scheller
CYChe Yang
Che Yang
YKYoichi Kurumida
Yoichi Kurumida
BCBruno E. Correia
Bruno E. Correia
Small-molecule responsive protein switches are crucial components to control synthetic cellular activities. However, the repertoire of small-molecule protein switches is insufficient for many applications, including those in the translational spaces, where properties such as safety, immunogenicity, drug half-life, and drug side-effects are critical. Here, we present a computational protein design strategy to repurpose drug-inhibited protein-protein interactions as OFF- and ON-switches. The designed binders and drug-receptors form chemically-disruptable heterodimers (CDH) which dissociate in the presence of small molecules. To design ON-switches, we converted the CDHs into a multi-domain architecture which we refer to as activation by inhibitor release switches (AIR) that incorporate a rationally designed drug-insensitive receptor protein. CDHs and AIRs showed excellent performance as drug responsive switches to control combinations of synthetic circuits in mammalian cells. This approach effectively expands the chemical space and logic responses in living cells and provides a blueprint to develop new ON- and OFF-switches.

1 December 2020 in Molecular Therapy
Verified
Journal Article
Open access
RRRaphaël B. Di Roberto
Raphaël B. Di Roberto
RCRocío Castellanos-Rueda
Rocío Castellanos-Rueda
SFSamara Frey
Samara Frey
DEDavid Egli
David Egli
RVRodrigo Vazquez-Lombardi
Rodrigo Vazquez-Lombardi
SRSai T. Reddy
Sai T. Reddy
In recent years, chimeric antigen receptor (CAR) T cell cancer immunotherapies have advanced substantially in the clinic. However, challenges related to safety persist; one major concern occurs when CARs trigger a response to antigen present on healthy cells (on-target, off-tumor response). A strategy to ameliorate this relies on the complex relationship between receptor affinity and signaling, such that one can engineer a CAR that is only activated by tumor cells expressing high antigen levels. Here, we developed a CAR T cell display platform with stable genomic expression and rapid functional screening based on interleukin-2 signaling. Starting with a CAR with high affinity toward its target antigen, we combined CRISPR-Cas9 genome editing and deep mutational scanning to generate a library of antigen-binding domain variants. This library was subjected to multiple rounds of selection based on either antigen binding or cell signaling. Deep sequencing of the resulting libraries and a comparative analysis revealed the enrichment and depletion of specific variants from which we selected CARs that were selectively activated by tumor cells based on antigen expression levels. Our platform demonstrates how directed evolution based on functional screening and deep sequencing-guided selection can be combined to enhance the selectivity and safety of CARs.

1 December 2021 in Trends in Biotechnology
Verified
Journal Article
Closed access
RCRocío Castellanos-Rueda
Rocío Castellanos-Rueda
RRRaphaël B. Di Roberto
Raphaël B. Di Roberto
FSFabrice S. Schlatter
Fabrice S. Schlatter
SRSai T. Reddy
Sai T. Reddy

14 February 2025 in Science Advances
Verified
Journal Article
Open access
RCRocío Castellanos-Rueda
Rocío Castellanos-Rueda
KWKai-Ling K. Wang
Kai-Ling K. Wang
JFJuliette L. Forster
Juliette L. Forster
ADAlice Driessen
Alice Driessen
JFJessica A. Frank
Jessica A. Frank
SRSai T. Reddy
Sai T. Reddy
Chimeric antigen receptor (CAR) T cells offer a promising cancer treatment, yet challenges such as limited T cell persistence hinder efficacy. Given its critical role in modulating T cell responses, it is crucial to understand how the CAR signaling architecture influences T cell function. Here, we designed a combinatorial CAR signaling domain library and performed repeated antigen stimulation assays, pooled screens, and single-cell sequencing to systematically investigate the impact of modifying CAR signaling domains on T cell activation and persistence. Our data reveal the predominant influence of membrane-proximal domains in driving T cell phenotype. Notably, CD40 costimulation was crucial for fostering robust and lasting T cell responses. Furthermore, we correlated in vitro generated CAR T cell phenotypes with clinical outcomes in patients treated with CAR T therapy, establishing the foundation for a clinically informed screening approach. This work deepens our understanding of CAR T cell biology and may guide future CAR engineering efforts.